SDZ:SIXSandoz Group Ltd Analysis
Data as of 2026-09-03 - not real-time
CHF 68.86
Latest Price
4/10Risk
Risk Level: Medium
Executive Summary
Sandoz Group AG trades at CHF 68.86, with its short-term moving averages stacked above the longer-term ones — a bullish trend structure. Over a rolling month the price has gained 3.5%. RSI sits at 44.8, which reads as neutral, and MACD momentum is bearish. Price has been bracketed by support at CHF 66.36 and resistance at CHF 75.90.
On valuation the read is overvalued — earnings multiple of 57.9 versus a 30.8 sector average, above the peer group. Analyst price targets sit 6.0% above the current price. Revenue is growing at 9.9% on a 5.5% profit margin. The 1.16% dividend yield looks covered by current payout levels.
The composite risk read is 4/10, putting it in moderate territory. With 30-day volatility of 36.7%, a beta of 0.07 and a maximum drawdown of 17.6%, position sizing matters here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
Across every horizon the signals point the same way: hold, at a conviction of 1 out of 10.
On valuation the read is overvalued — earnings multiple of 57.9 versus a 30.8 sector average, above the peer group. Analyst price targets sit 6.0% above the current price. Revenue is growing at 9.9% on a 5.5% profit margin. The 1.16% dividend yield looks covered by current payout levels.
The composite risk read is 4/10, putting it in moderate territory. With 30-day volatility of 36.7%, a beta of 0.07 and a maximum drawdown of 17.6%, position sizing matters here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
Across every horizon the signals point the same way: hold, at a conviction of 1 out of 10.
Top Market Events
Sandoz Group SWX:SDZ has agreed US settlements that resolve long running investigations into generic drug pricing.Strong biosimilar performance and strategic launches offset pricing pressures, boosting core EPS by 17%.Sandoz Group AG / Key word s : Half Year Results Sandoz delivers strong H1 2026 results, with outstanding biosimilar...
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 3/10
Key Factors
- Short-term moving averages stacked above long-term ones
- Trading above the 200-day average of 64.21
- MACD momentum is negative
Medium Term
1–3 yearsNeutral
Model confidence: 2/10
Key Factors
- Short-term moving averages stacked above long-term ones
- P/E of 57.9 versus sector average of 30.8
- Trading above the 200-day average of 64.21
Long Term
> 3 yearsNeutral
Model confidence: 1/10
Key Factors
- P/E of 57.9 versus sector average of 30.8
- Analyst targets imply +6.0% versus the current price
- Dividend yield of 1.16%
Key Metrics & Analysis
Financial Health
Revenue Growth9.90%
Profit Margin5.53%
P/E Ratio57.9
ROE7.25%
ROA3.07%
Debt/Equity68.92
P/B Ratio4.1
Op. Cash FlowCHF1.9B
Free Cash FlowCHF1.4B
Industry P/E30.8
Technical Analysis
TrendBullish
RSI44.8
SupportCHF 66.36
ResistanceCHF 75.90
MA 20CHF 71.87
MA 50CHF 69.41
MA 200CHF 64.21
MACDBearish
VolumeDecreasing
Fear & Greed Index94.29
Valuation
Fair ValueCHF 51.66
Target PriceCHF 73.01
Upside/Downside6.02%
GradeOvervalued
TypeGrowth
Dividend Yield1.16%
Risk Assessment
Beta0.07
Volatility36.72%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.